Christopher Frigon advises entrepreneurs, investors and emerging and seasoned companies in domestic and international corporate finance transactions, mergers and acquisitions and corporate governance issues.  Mr. Frigon’s focus includes shareholder arrangements, angel and venture capital financings, corporate restructurings, strategic transactions and investments, U.S. securities laws and general corporate matters.  Mr. Frigon has worked on many complex and sophisticated transactions including high-yield financings, investment-grade debt offerings, IPOs, debt restructuring transactions and other U.S. and cross-border capital-raising transactions for major investment banks, private equity firms and hedge funds and domestic and international corporate issuers.

In addition, Mr. Frigon regularly serves as outside general counsel on an on-going basis for companies in a variety of industries including biotechnology, venture capital, software and technology and media.  Mr. Frigon is currently member of the Board of Directors and Corporate Secretary of Adjuvance Technologies Inc., a biopharmaceutical company.

Mr. Frigon has significant international experience, particularly in Latin America, having closed a number of cross-border transactions particularly in Argentina, Brazil, Mexico, Chile and Colombia, each valued at over $100 million, and is fluent in Spanish and Portuguese.

Mr. Frigon is a founding partner at Frigon Maher & Stern LLP, which he launched in 2010 after eight years as a securities and corporate attorney at Simpson Thacher & Bartlett LLP in New York City.

During Mr. Frigon’s career he has represented companies of all sizes from diverse industries on a wide range of transactions including KKR and Blackstone portfolio companies in connection with leverage financings and other corporate matters; top investment banks such as J.P. Morgan, Citi and Morgan Stanley in connection with strategic transactions, including innovative deals for the hedge fund groups at Goldman Sachs, Lehman Brothers and Merrill Lynch; and financings and other securities and corporate matters for Fortune 500 companies such as Wyeth, Northwest Airlines, Peabody Energy and Warner Music Group. In addition, Mr. Frigon has represented various technology and emerging growth companies in connection with corporate and financing matters, executive compensation, intellectual property, commercial contracts and governance issues.

Representative Domestic Transactions:

Goldman Sachs and Lehman Brothers in connection with the first-ever $2 billion, Rule 144A medium term note program for a hedge fund, Citadel Investment Group;

Citigroup in connection with a $500 million, Rule 144A offering of convertible notes by SBA Communications;

J.P. Morgan in connection with a $150 million, Rule 144A offering of high yield notes for Plastipak Holdings; and

Peabody Energy Corporation in connection with the SEC registered offering of $900 million in high yield notes and approximately $700 million in convertible junior subordinated notes, an innovative hybrid convertible security.

Representative Technology and Emerging Company Transactions:

A vaccine technology company and spin-off of Memorial Sloan Kettering in connection with corporate and IP matters, as well as acting as its outside general counsel;

AOL and Time Warner Inc. on an on-going basis for three years in connection with a strategic technology investments, providing corporate governance, M&A, contractual and financial solutions in connection with such investments; and

A human resources application software company in connection with an offering of series preferred shares, and a modeling agency in connection with the launch of an app-based subsidiary and convertible note financing.

Representative Cross-Border Transactions:

Cresud S.A. (an Argentine company) in connection with a $288 million SEC registered global offering of rights to subscribe for stock and warrants listed on the Nasdaq;

Exito S.A. (a Colombian company) in connection with a $390 million Rule 144A/Reg S offering of Global Depositary Receipts;

Empresas Iansa S.A. (a Chilean company) in connection with a $100 million Rule 144A/Reg S offering of high yield note;

OdontoPrev S.A. (a Brazilian company) in connection with a $200 million IPO in Brazil and 144A/Reg S offering outside Brazil; and

Vivo Participaçoes S.A. (a Brazilian company) in connection with its multi-billion dollar acquisition of four publicly traded telecom companies, three of which were listed on the NYSE.